Bexitrol F
Rx50 mcg+250 mcg • Multidose Dry Powder Inhaler (MDPI)
More from Bexitrol F
Other strengths and forms by Beximco Pharmaceuticals Ltd.
Indications & Uses
Bexitrol F is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Detailed dosing reference is not available yet. Please follow your prescription and consult your pharmacist.
Side Effects
Side-effect information is not available for this brand yet.
Cautions & Contraindications
Warnings & Precautions
Salmeterol + Fluticasone Propionate should not be started in a patient who is having an asthma exacerbation, or whose asthma is unstable or getting worse quickly. This inhalation capsule is not for relieving sudden symptoms, which need a fast and short-acting bronchodilator (e.g. salbutamol). Patients should be told to keep their relief medicine with them at all times. Serious asthma-related adverse events and exacerbations may occur during treatment with this inhalation capsule. Patients should be asked to carry on with treatment, but to see a doctor if their asthma symptoms stay uncontrolled or get worse after they start it. As with other inhaled therapy, paradoxical bronchospasm can happen, with wheezing increasing straight after a dose. Treat it immediately with a fast and short-acting inhaled bronchodilator. Stop this inhalation capsule at once, assess the patient and start alternative therapy if necessary. The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache, have been reported. They tend to be transient and to lessen with regular therapy. In studies of COPD patients using the salmeterol/fluticasone inhaler, pneumonia was reported more often. Physicians should stay alert for pneumonia in COPD patients, because the clinical features of pneumonia and exacerbation often overlap. This inhalation capsule contains an inhaled corticosteroid (fluticasone propionate). Any inhaled corticosteroid can cause systemic effects, particularly at high doses prescribed for long periods. These effects are much less likely than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation and (very rarely) behavioral disturbances in children and adolescents, decrease in bone mineral density, cataract and glaucoma. For this reason the patient should be reviewed regularly, and the dose of the inhaled corticosteroid should be reduced to the lowest dose at which effective control is maintained.
Contraindications
Salmeterol + Fluticasone Propionate must not be given to anyone with a history of hypersensitivity to salmeterol xinafoate, fluticasone propionate or any of the excipients. It is also contraindicated as the primary treatment of status asthmaticus, or of other acute episodes of asthma where intensive measures are required.
Pregnancy & Breastfeeding
Pregnancy
This inhalation capsule should be considered during pregnancy only if the expected benefit to the mother is greater than any possible risk to the fetus. There isn't enough experience of salmeterol xinafoate and fluticasone propionate in human pregnancy. Animal studies of reproductive toxicity, with either medicine alone or both together, showed the fetal effects expected at excessive systemic exposure levels of a potent beta-2-adrenoreceptor agonist and glucocorticosteroid.
Lactation
For breast-feeding mothers, this inhalation capsule should be considered only if the expected benefit to the mother is greater than any possible risk to the child. There isn't enough experience of salmeterol xinafoate and fluticasone propionate in human lactation. After inhaled therapeutic doses, the plasma concentrations of salmeterol and fluticasone propionate are very low, so the concentrations in human breast milk are likely to be correspondingly low. Studies in lactating animals support this, as low concentrations were measured in the milk. There are no data available for human breast milk.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Children who use an orally inhaled corticosteroid, which includes the fluticasone propionate in Salmeterol + Fluticasone Propionate, may grow more slowly than normal. Nobody yet knows what this slower growth means in the long run, including whether it affects a child's final adult height.
Overdose
No human overdose data has been reported for the Salmeterol + Fluticasone Propionate inhaler. Data on overdose with each of the two drugs are given below.
Salmeterol: The signs and symptoms of Salmeterol overdose are seizures, angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise and insomnia. Hypokalemia and hyperglycemia may also be seen. Treatment is to stop Salmeterol and give appropriate cardioselective beta-blocking agents, which should be used with caution in patients with a history of bronchospasm.
Fluticasone Propionate: Taking an acute inhaled dose of Fluticasone Propionate above the recommended amount may lead to temporary suppression of adrenal function. This doesn't need emergency action, because adrenal function recovers in a few days. Chronic overdose of inhaled Fluticasone Propionate may lead to adrenal suppression, and monitoring of adrenal reserve may be necessary. In cases of Fluticasone Propionate overdose, Salmeterol + Fluticasone Propionate inhaler therapy may still be continued at a suitable dosage for symptom control.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
The Salmeterol + Fluticasone Propionate inhaler comes in a pressurised canister. Don't puncture or break it, and don't burn it, even when it seems empty. Store it below 30°C and out of direct sunlight or heat. Take care that none gets into the eyes. Children should not be able to reach it.
Drug Interactions
Common questions about Bexitrol F 50 mcg+250 mcg
What is Bexitrol F 50 mcg+250 mcg Multidose Dry Powder Inhaler (MDPI)?
Bexitrol F 50 mcg+250 mcg Multidose Dry Powder Inhaler (MDPI) is a medicine that contains Salmeterol + Fluticasone Propionate. It is made by Beximco Pharmaceuticals Ltd. It belongs to the Long-acting selective β-adrenoceptor stimulants group of medicines.
What is Bexitrol F used for?
Bexitrol F is used for: Asthma.
Can I take Bexitrol F during pregnancy or while breastfeeding?
Pregnancy This inhalation capsule should be considered during pregnancy only if the expected benefit to the mother is greater than any possible risk to the fetus. There isn't enough experience of salmeterol xinafoate and fluticasone propionate in human pregnancy. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Bexitrol F?
No human overdose data has been reported for the Salmeterol + Fluticasone Propionate inhaler. Data on overdose with each of the two drugs are given below. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Bexitrol F?
The Salmeterol + Fluticasone Propionate inhaler comes in a pressurised canister. Don't puncture or break it, and don't burn it, even when it seems empty.
Can I take other medicines with Bexitrol F?
Some medicines can interact with Salmeterol + Fluticasone Propionate, for example: Fluticasone Propionate, Ritonavir, Ketoconazole. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Bexitrol F?
Bexitrol F is a prescription (Rx) medicine. Take it as your doctor advises.